drugset / Trial / NCT02134314

C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI

NCT02134314

Phase 1/2 Completed 70 enrolled Cedars-Sinai Medical Center
RandomizedParallel-groupTriple-blindPrevention

Summary

The use of C1INH (Berinert) in patients receiving deceased donor kidney transplants with high risk for delayed graft function (DGF) may show significant improvement in outcomes post transplant compared with patients that do not receive C1INH treatment. Complement activation has been detected in animal models and human kidneys with ischemic reperfusion injury (IRI) and inflammatory cell infiltrates. By blocking complement activation the investigators hope to improve kidney graft function post transplant in these recipients.

Timeline

Start
2014-09
Primary completion
2017-03-13
Completion
2017-03-13

Drugs

EvaluationDrugModalityDoseRoute
Subject CINRYZE Protein / enzyme biologic 50 iu/kg Intravenous